2026-03-27 11:33:48
Rocket Pharmaceuticals Receives FDA Approval for KRESLADI™ Gene Therapy for Pediatric Patients with Severe LAD-I
Expected Stock impact: Very Positive
On March 27, 2026, Rocket Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), a groundbreaking autologous hematopoietic stem cell-based gene therapy. This therapy is specifically indicated for the treatment of pediatric patients suffering from severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in the ITGB2 gene, where no human leukocyte antigen-matched sibling donor is available for allogeneic hematopoietic stem cell transplant. The approval of KRESLADI marks a significant milestone as it is the first FDA-approved gene therapy for children with severe LAD-I, a life-threatening genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment. The FDA's decision was based on the therapy's ability to increase neutrophil CD18 and CD11a surface expression, with confirmation of clinical benefit to be assessed through ongoing clinical studies and a post-marketing registry. In conjunction with the approval, Rocket Pharmaceuticals has been awarded a Rare Pediatric Disease Priority Review Voucher (PRV), which is designed to incentivize the development of therapies for rare pediatric diseases. The company plans to explore strategic options to monetize the PRV to enhance financial flexibility and maximize shareholder value. This approval is expected to have a large positive impact on Rocket Pharmaceuticals' stock price, reflecting the company's commitment to addressing high unmet medical needs in pediatric populations.
